Bayer stock forecast: Third-party price targets
Bayer is a German life sciences company listed in Europe, with operations across pharmaceuticals, consumer health and crop science. Explore third-party BAYN price targets and technical analysis.
Bayer AG (BAYN) is trading around €44.80 in Thursday’s European session, moving within an intraday range of approximately €43.95–€45.70 on Capital.com’s price feed as of 4:31pm UTC on 5 February 2026. Past performance is not a reliable indicator of future results.
The stock is trading as investors focus on upcoming catalysts, including Bayer’s planned publication of fourth-quarter and full-year 2025 results on 24 February 2026 and an analyst conference on 25 February 2026. These events are expected to provide additional detail on performance across its Pharmaceuticals, Consumer Health and Crop Science divisions (The Globe and Mail, 18 November 2025). Market attention is also on clinical developments, with Bayer scheduled to present detailed Phase III OCEANIC-STROKE trial results for its anticoagulant candidate Asundexian on 5 February 2026 at the International Stroke Conference, followed by an investor webinar on 6 February 2026 (Yahoo Finance, 27 January 2026). Trading in Bayer shares is also unfolding against a broader backdrop of steady European equity markets, with the STOXX 600 hovering near record levels as investors assess corporate earnings and await the European Central Bank’s policy decision later in the day (Reuters, 5 February 2026).
Bayer stock forecast 2026–2030: Third-party price targets
As of 5 February 2026, third-party Bayer stock predictions show a broad dispersion of views, with different providers reporting both individual broker objectives and aggregated one-year consensus levels. The following summaries outline selected third-party targets, associated timeframes and the key assumptions cited over this recent period.
Seeking Alpha (equity research note)
Seeking Alpha contributor analysis cites a Bayer price target of €35 per share as part of a Buy-rated thesis framed over the 2025–2026 horizon. The author notes that this target reflects expectations around restructuring, potential asset disposals and the management of litigation risk, while also highlighting that execution risk and legal outcomes remain material uncertainties (Seeking Alpha, 19 January 2026).
BofA Securities (broker update via newswire)
BofA Securities raised its Bayer 12-month price target to €55 from €35, according to a syndicated analyst-rating report, while maintaining a positive stance on the stock. The bank is reported to have lifted its target following greater confidence after a U.S. Supreme Court development related to glyphosate litigation, while the note also points to ongoing operational and balance-sheet considerations (Investing.com, 19 January 2026).
Nasdaq (Xetra BAYN) (consensus snapshot)
Nasdaq reports that the average one-year price target for Bayer AG (BAYN) was revised to €42.36 per share. The service notes that this consensus, derived from multiple analyst submissions, spans a range from €23.23 to €57.75, reflecting differing assumptions around earnings, litigation exposure and valuation (Nasdaq, 3 February 2026).
MarketScreener (analyst-compiled consensus)
MarketScreener’s Bayer consensus page shows a consolidated BAYN stock forecast averaging in the low-€40s area, with individual analyst objectives clustering both below and above that midpoint. The platform notes that these figures aggregate multiple broker models and recommendations, capturing a range of views on Bayer’s deleveraging trajectory, pharmaceuticals pipeline and litigation provisions (MarketScreener, 4 February 2026).
Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.
BAYN stock price: Technical overview
The BAYN stock price is trading around €44.80 as of 4:31pm UTC on 5 February 2026, holding above a rising moving-average cluster, with the 20-, 50-, 100- and 200-day simple moving averages grouped near approximately €44, €38, €33 and €30 respectively. The 20-day SMA remains above the 50-day, preserving a short-term bullish alignment, while the 14-day RSI near 63 sits in the upper-neutral zone and the ADX around 54 points to an established trend.
On the upside, the nearest classic resistance sits at the R1 pivot around 48.57, and a sustained daily close above this level would bring the R2 area near 52.58 back into view as the next technical reference. On pullbacks, initial support is marked by the classic pivot near 42.72, with the 100-day SMA around 32.92 representing the next notable longer-term level. A decisive break below that zone could increase the risk of a move toward the S1 area near 38.71 (TradingView, 5 February 2026).
This technical analysis is provided for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.
Bayer share price history (2024–2026)
BAYN’s stock price has undergone a notable turnaround over the past two years. On 5 February 2024, the stock was trading in the high-€20s, and by early 2025 it remained in the €19–€22 range. From spring 2025, BAYN began to recover, rising from around €21 in April to above €30 by late November, before accelerating into December and closing at €33.45 on 5 December 2025.
The recovery extended into 2026, with the share price advancing from around €38 at the start of January to the mid-€40s by late in the month, briefly reaching intraday highs above €47 on 28 January 2026. As of 5 February 2026, Bayer was trading at €44.80, placing it well above its 2024 trading range and marking a significant rebound over the two-year period, although still below levels seen prior to major litigation challenges. This description is based solely on the historical price data referenced for Bayer shares over the period.
Past performance is not a reliable indicator of future results.
Bayer (BAYN): Capital.com analyst view
Bayer’s share price has staged a notable recovery over the past two years, moving from the low-€20s in early 2025 to the mid-€40s by early February 2026 on Capital.com’s feed. More recent trading has been characterised by narrower intraday ranges following a strong late-2025 advance. This move has coincided with renewed market focus on restructuring initiatives, debt reduction and pipeline execution, alongside anticipation around the publication of full-year 2025 results and further detail on pharmaceuticals growth and cash-flow generation. At the same time, the higher share price means that a greater proportion of Bayer’s valuation now reflects expectations that management can deliver on turnaround plans and that recent price momentum is supported by fundamentals rather than sentiment alone.
From a broader perspective, the Bayer investment case continues to balance potential upside from restructuring progress and new medicines against ongoing risks related to litigation, leverage and execution. Rating agencies and external analysts continue to flag sizeable provisions, pressure on credit metrics and the possibility that additional legal charges or weaker-than-expected cash generation could weigh on financial flexibility. In contrast, some research highlights progress on settlements, portfolio optimisation and targeted growth in selected pharmaceutical brands. One interpretation is that addressing legacy issues while investing in higher-growth areas could, over time, support a more sustainable operating profile, while an alternative view is that prolonged legal uncertainty, competitive pressures or disappointing earnings could limit further re-rating and reintroduce volatility in the share price.
Capital.com’s client sentiment for Bayer CFDs
As of 5 February 2026, Capital.com client positioning in Bayer CFDs shows 95.1% buyers versus 4.9% sellers, representing a heavily one-sided tilt toward long positions and placing buyers ahead by around 90 percentage points. This distribution indicates that positioning is currently skewed rather than evenly balanced between directional views. This snapshot reflects open positions on Capital.com and is subject to change.
Summary – Bayer 2026
- Bayer’s share price on Capital.com moved from the low-€20s in early 2025 to the low-€30s by December, before extending its advance into the mid-€40s in early 2026.
- Technical indicators show Bayer trading above its 20-, 50-, 100- and 200-day moving averages, with a 20-over-50 alignment and a 14-day RSI in upper-neutral territory.
- Recent price behaviour has been influenced by restructuring efforts, litigation developments and anticipation around full-year 2025 results, with analysts and rating agencies continuing to highlight both potential recovery drivers and ongoing legal and balance-sheet risks.
Past performance is not a reliable indicator of future results.
FAQ
Who owns the most Bayer stock?
Bayer has a widely distributed shareholder base, with no single controlling owner. The company’s largest shareholders typically include institutional investors such as global asset managers, pension funds and insurance groups, alongside retail investors. Public disclosures show that holdings can change over time as institutions adjust exposure in response to earnings, litigation developments or index rebalancing. As a listed company, Bayer is subject to ongoing transparency requirements regarding significant shareholdings.
What is the five-year Bayer share price forecast?
There is no single, agreed five-year BAYN stock forecast. Most publicly available projections focus on shorter horizons, usually 12 months, and show a wide range of outcomes. Longer-term expectations depend on factors such as litigation resolution, balance-sheet management, pharmaceuticals pipeline progress and agricultural market conditions. As a result, any extended forecast involves a high degree of uncertainty, and published estimates are generally best viewed as scenarios rather than predictions.
Is Bayer a good stock to buy?
Whether Bayer is considered attractive depends on individual objectives, risk tolerance and time horizon. Some analysts highlight potential upside linked to restructuring efforts, asset optimisation and new drug development, while others emphasise ongoing litigation exposure, leverage and execution risks. As a result, views on the stock remain mixed. This information is provided for general market context only and does not constitute investment advice or a recommendation.
Could Bayer stock go up or down?
Yes, Bayer’s share price could move in either direction. Like other large-cap pharmaceutical and life sciences companies, its stock can react to earnings releases, legal developments, clinical trial data, regulatory decisions and broader market conditions. Positive or negative developments in any of these areas may influence investor sentiment and volatility. Share prices are inherently uncertain, and past movements do not reliably indicate future performance.
Should I invest in Bayer stock?
Deciding whether to invest in Bayer shares is a personal decision that should take into account financial goals, risk appetite and overall portfolio composition. Investors often weigh potential recovery or growth drivers against risks such as litigation costs, debt levels and competitive pressures. Seeking independent financial advice may be appropriate before making investment decisions. This content is for informational purposes only and is not investment advice.
Can I trade Bayer CFDs on Capital.com?
Yes, you can trade Bayer CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.